Jinxin returns to the black on U.S. recovery, focus on high-end clients
Fertility services company Jinxin Fertility Group Ltd. (1951.HK) said on Tuesday it swung to profitability in the first half of this year from a loss a year earlier, as its…
Beauty Farm first-half profit rises on Siyanli acquisition
Beauty clinic operator Beauty Farm Medical and Health Industry Inc. (2373.HK) announced on Monday it expects to report its revenue for the first half of 2026 totaled 1.88 billion yuan…
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
The Chinese biotech said the enrollment marks a key milestone for its advancing bile duct cancer treatment By Teri Yu Clinical-stage biotech firm TransThera Sciences (Nanjing) Inc. (2617.HK) said it…
Shaanxi Micot shares nearly double in Hong Kong trading debut
Shares of drugmaker Shaanxi Micot Pharmaceutical Technology Co. Ltd. (2335.HK) jumped in their Hong Kong trading debut on Wednesday, after the company raised HK$989 million ($126 million) by selling about…
HJ Science tumbles in Hong Kong trading debut
Shares of clinical-stage biotechnology company HJ Science Co. Ltd. (6132.HK) opened flat in their Hong Kong trading debut on Tuesday, but quickly headed south and ended their first day down…
Jiangxi Bio launches $60 million IPO, warns of sharp profit decline this year
Human tetanus antitoxin (TAT) maker Jiangxi Institute of Biological Products Inc. (6915.HK) launched its Hong Kong IPO on Monday, offering 36.23 million shares for HK$13.06 each to raise HK$473 million…
WuXi AppTec sues to get its name removed from U.S. blacklist
Pharmaceutical services provider WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) has sued the U.S. Defense Department, seeking to have its name removed from the department’s list of Chinese companies with military…
